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Inhibition of miR-29 has a 
significant lipid-lowering benefit 
through suppression of lipogenic 
programs in liver
C. Lisa Kurtz1, Emily E. Fannin1, Cynthia L. Toth2, Daniel S. Pearson3, Kasey C. Vickers2 & 
Praveen Sethupathy1,4
MicroRNAs (miRNAs) are important regulators and potential therapeutic targets of metabolic 
disease. In this study we show by in vivo administration of locked nucleic acid (LNA) inhibitors 
that suppression of endogenous miR-29 lowers plasma cholesterol levels by ~40%, commensurate 
with the effect of statins, and reduces fatty acid content in the liver by ~20%. Whole transcriptome 
sequencing of the liver reveals 883 genes dysregulated (612 down, 271 up) by inhibition of miR-
29. The set of 612 down-regulated genes are most significantly over-represented in lipid synthesis 
pathways. Among the up-regulated genes are the anti-lipogenic deacetylase sirtuin 1 (Sirt1) and 
the anti-lipogenic transcription factor aryl hydrocarbon receptor (Ahr), the latter of which we 
demonstrate is a direct target of miR-29. In vitro radiolabeled acetate incorporation assays confirm 
that pharmacologic inhibition of miR-29 significantly reduces de novo cholesterol and fatty acid 
synthesis. Our findings indicate that miR-29 controls hepatic lipogenic programs, likely in part 
through regulation of Ahr and Sirt1, and therefore may represent a candidate therapeutic target for 
metabolic disorders such as dyslipidemia.
The liver is the primary site of lipid synthesis and metabolism1,2. Proper hepatic control of lipid home-
ostasis is governed in large part by complex gene regulatory networks. In the last ten years, microRNAs 
(miRNAs) have emerged as important components of these networks3–5. The dysregulation of miRNA 
activity has been linked to various metabolic disorders of the liver such as hyperlipidemia6,7, steatosis8,9, 
insulin resistance10,11, and obesity12,13. The first miRNA that was shown to have an important role in 
lipid biology is miR-12214, one of the most abundant miRNAs in the mammalian liver15. In vivo studies 
in mice demonstrated that miR-122 is involved in the regulation of lipid synthesis14, catabolism14, and 
secretion16, and also has essential anti-inflammatory and anti-tumorigenic functions in the liver17. More 
recently, miR-122 was shown to control plasma cholesterol levels in humans as well18.
Since the discovery of miR-122, a growing number of miRNAs have been implicated in the control of 
lipid homeostasis. For example, Cheung et al. found that several miRNAs, including miR-27b, miR-34a, 
and miR-30, are more significantly altered in non-alcoholic steatohepatitis than miR-12219. Subsequent 
studies in mice demonstrated that miR-27b is a regulatory hub in hepatic lipid metabolic networks6, 
miR-34a contributes to hepatic steatosis via repression of sirtuin 1 (Sirt1)20, and miR-30 controls lipid 
synthesis and lipoprotein secretion21. In vivo studies in both mice and non-human primates showed that 
miR-33a and miR-33b, encoded within the genes SREBF2 and SREBF1, respectively, are critical regulators 
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of cholesterol balance22–24. Most recently, miR-223 was identified as a master coordinator of cholesterol 
uptake, efflux, and synthesis in the liver25. These and other related findings indicate that hepatic miRNAs 
are central to the governance of lipid homeostasis and are candidate therapeutic targets in metabolic 
disease.
We recently demonstrated that hepatic miR-29 is aberrantly elevated in two different models of met-
abolic dysfunction: high-fat diet-induced obese mice and Zucker Diabetic Fatty (fa/fa) rats26. Notably, 
miR-29 levels were restored in fa/fa rats upon treatment with Pioglitazone, which improves both insu-
lin sensitivity and lipid profiles. We also showed in vitro that miR-29 fine-tunes the levels of key lipid 
metabolic genes26. To follow-up on these findings, we sought to investigate in mice the effects of loss of 
miR-29 function on circulating lipids using in vivo locked nucleic acid (LNA) technology.
Results
LNA administration in vivo strongly inhibits the miR-29 family in numerous tissues. Two 
independent sets of 10-12 week-old C57BL/6 J female mice were injected with either saline (set 1, n = 6; 
set 2, n = 6) or locked nucleic acid inhibitors of miR-29abc (LNA29; set 1, n = 6; set 2, n = 8). As a 
control, another set of 10-12 week-old C57BL/6 J female mice were injected with either saline (n = 6) or 
a locked nucleic acid inhibitor of miR-27b (LNA-control, n = 5) (Methods). Seven days post injection 
the animals were sacrificed and tissue was collected. To determine the efficacy of endogenous miR-29 
knock-down after treatment with LNA29, we examined the levels of miR-29 in liver. As expected, hepatic 
miR-29 expression was dramatically reduced in LNA29 treated animals (Fig.  1a), but not significantly 
altered in LNA-control treated animals (Supplementary Fig. S1). Furthermore, the levels of a validated 
miR-29 target gene, collagen type I alpha 1 (Col1a1)27, were increased significantly in multiple tissues 
including the kidney (2.9 fold), liver (2.2 fold), skeletal muscle (1.9 fold), lung (1.4 fold) and spleen 
(1.3 fold) (Fig.  1b). Col1a1 levels were unchanged in brain, which is consistent with previous reports 
that tail-vein injected LNAs do not efficiently cross the blood-brain barrier. Another established miR-29 
target gene, collagen type III alpha 1 (Col3a1)27, was also increased in the livers of LNA29-treated mice 
(Supplementary Fig. S1), but both Col1a1 and Col3a1 were not significantly altered in the livers of mice 
treated with LNA-control (Supplementary Fig. S1). Plasma ALT was measured to test for general liver 
damage and the levels were not significantly altered in LNA29-treated animals (Fig. 1c). Taken together, 
these data indicate that systemic administration of LNA29 leads to specific and potent suppression of 
miR-29 activity with no overt liver toxicity.
Inhibition of miR-29 leads to a dramatic reduction in circulating cholesterol and triglycer-
ides. Next, we assessed the effect of miR-29 inhibition on circulating lipid levels (Methods). We meas-
ured total cholesterol and triglycerides, as well as glucose and β -hydroxybutyrate (ketones), in plasma 
samples collected one week prior to dosing with LNA29 or saline and again six days post-dose. Pre-dose 
levels were comparable across all mice (Supplementary Fig. S2). Post-dose plasma cholesterol levels in 
LNA29-treated mice (n = 14) were reduced relative to saline-treated controls (n = 12) by ~40% (Fig. 2a), 
which matches what has been observed previously with the use of statin drugs. All 14 mice treated with 
LNA29 exhibited reduced plasma cholesterol compared to pre-dose levels, with an average reduction of 
21.2 mg/dL (Fig. 2b). Plasma triglycerides were also significantly reduced in LNA29-treated animals com-
pared to saline-treated controls (~15% decrease) (Fig.  2c). Glucose and β -hydroxybutyrate levels were 
not significantly altered in LNA29 treated mice (Fig. 2d,e). Neither plasma cholesterol nor triglycerides 
were altered in mice treated with LNA-control (n = 5) (Supplementary Fig. S3). Taken together, these 
data suggest a specific and strong effect of miR-29 inhibition on circulating lipids.
Inhibition of miR-29 dysregulates more than 850 genes in mouse liver. The liver is the primary 
site of lipid synthesis. Therefore, in order to examine the mechanisms underlying the circulating lipid 
phenotype, we performed deep sequencing of messenger RNAs from the livers of both LNA29-treated 
(n = 6) and saline-treated mice (n = 6) (Methods). The mRNA expression levels of 883 genes were signifi-
cantly altered (271 up, 612 down) in the livers of LNA29-treated mice compared to saline-treated controls 
(Fig.  3a, Supplementary Table S1; GEO accession number GSE63493). Suppression of miR-29 activity 
should lead to up-regulation of direct target genes. Accordingly, we found that only the up-regulated 
gene set was significantly enriched for predicted target sites of miR-29 and no other miRNA (Fig. 3b,c), 
which demonstrates the efficacy and specificity of LNA29. Interestingly, the 612 down-regulated genes 
were most significantly over-represented in lipid synthesis pathways (Fig. 3d, Supplementary Tables S2 
and S3), whereas the up-regulated gene set was not enriched for any lipid-related pathway (Fig.  3e, 
Supplementary Tables S4 and S5). These data indicate that inhibition of miR-29 leads to widespread 
repression of genes in pathways that govern both fatty acid and cholesterol synthesis.
Inhibition of miR-29 represses fatty acid synthesis and reduces fatty acid content in the 
liver. Several genes in the fatty acid synthesis pathway were significantly down-regulated by RNA-seq 
in the livers of LNA29-treated mice (Fig.  4a). We validated these findings using real-time quantitative 
PCR (RT-qPCR) for Srebf1 (25% decrease), Mlxipl/ChREBP (50%), Acly (20%), Acaca (35%), Fasn (50%), 
and Scd1 (50%) (Fig. 4b). Srebf1 and ChREBP are master transcriptional regulators of lipid synthesis28,29, 
and Acly, Acaca, Fasn, and Scd1 are key enzymes in fatty acid synthesis. We confirmed by immunoblot 
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analysis that Scd1 protein was also significantly down-regulated (~25% loss) in LNA29-treated livers 
(Fig. 4c).
Based on these data, we hypothesized that inhibition of miR-29 leads to suppression of de novo fatty 
acid synthesis. To test this hypothesis we transfected human hepatoma (Huh7) cells with LNAs against 
miR-29a, which reduced fatty acid production by ~70% (Fig.  4d). LNAs against miR-29bc conferred a 
very similar effect (data not shown). Consistent with this finding, inhibition of miR-29 in vivo signifi-
cantly reduced (~20% decrease) total fatty acid content in the livers of the LNA29-treated mice (n = 14) 
compared to saline-treated controls (n = 12) (Fig. 4e). Among the long-chain fatty acids, palmitic acid 
(C16:0), stearic acid (C18:0), homogamma-linolenic acid (GLA, C20:3), arachidonic acid (C20:4), docos-
apentaenoic (DPA, C22:5) and docosahexaenoic acid (DHA, C22:6) were each significantly reduced 
(Fig. 4f). Palmitic acid is the most common fatty acid in animals and is produced by enzymatic activity 
of Fasn, which we showed is significantly reduced in the livers of LNA29-treated mice (Fig. 4a,b).
Inhibition of miR-29 represses the cholesterol synthesis pathway but slightly increases total 
hepatic cholesterol levels. Numerous genes in the cholesterol synthesis pathway were significantly 
down-regulated in the livers of LNA29-treated mice (Fig. 5a). We validated these findings using RT-qPCR 
for Srebf2 (35% decrease), Mvk (55%), Cyp51 (55%), Sqle (75%), and Idi1 (65%) (Fig. 5b). Srebf2, a mas-
ter transcriptional regulator of cholesterol homeostasis28, is co-transcribed with miR-33a. We examined 
Figure 1. In vivo LNA29 administration effectively inhibits the miR-29 family in the liver. (a,b) RT-
qPCR analysis of LNA29-treated (20 mg/kg) C57BL/6 J female mice (n = 14) with saline-treated age-, 
gender-, and strain-matched controls (n = 12) shows that endogenous expression of hepatic miR-29 is 
dramatically reduced (a); expression of Col1a1, a validated target of miR-29, is significantly elevated in 
several tissues including liver (b); U6 and Rps9 were used as expression normalizers for miRNA and gene 
analysis, respectively. (c) Plasma alanine transaminase (ALT) measurements (IU/L) are shown for LNA29-
treated animals (n = 6) and saline treated controls (n = 5). *p < 0.05; **p < 0.01; ***p < 0.005; p-values were 
calculated by two-tailed unpaired Student’s t-test. Error bars represent standard error of the mean.
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hepatic levels of miR-33a as a marker of transcription at the Srebf2 locus and found that it was decreased 
by ~30% (Fig. 5c).
Interestingly, unlike most of the other enzymes in the cholesterol synthesis pathway, the rate-limiting 
enzyme, 3-Hydroxy-3-Methylglutaryl-CoA Reductase (Hmgcr), was not down-regulated by LNA29 
(fold-change = 1.2) (Fig. 5a). Bioinformatic analysis revealed that in contrast to most other cholesterol-
ogenic genes, Hmgcr is predicted to be a direct target of miR-29. To test this prediction, we performed 
standard luciferase and site-directed mutagenesis assays with the 3′ UTR of HMGCR (Methods). Relative 
levels of luciferase activity were significantly decreased in the presence of miR-29a mimic for the plasmid 
with the HMGCR 3′ UTR, while a single point mutation in the miR-29 target site significantly (though 
not completely) rescued this effect (Supplementary Fig. S4). These results suggest that miR-29 inhibition 
in vivo likely alleviates miR-29-mediated direct repression of Hmgcr, thereby counteracting the overall 
suppressive effect of miR-29 inhibition on the cholesterol synthesis pathway.
Although Hmgcr is not significantly altered at the mRNA level in LNA29-treated livers, because most 
other genes in the cholesterol synthesis pathway are significantly down-regulated by miR-29 inhibition, 
we hypothesized that inhibition of miR-29 leads to an overall decrease in de novo cholesterol synthesis. 
To test this hypothesis, Huh7 cells were transfected as before with either LNA29a or LNA29bc. The 
knockdown of miR-29a significantly reduced acetate incorporation into cholesterol (Fig.  5d) and the 
results were very similar for LNA29bc (data not shown). However, notably, LNA29-treatment in vivo led 
to a modest but significant increase in total hepatic cholesterol levels (fold-change = 1.2) (Fig. 5e), sug-
gesting that miR-29 may control not only cholesterol synthesis, but also other pathways that contribute 
to total intracellular cholesterol levels.
Figure 2. Inhibition of miR-29 leads to a significant reduction of plasma cholesterol and triglycerides. 
(a,c–e) Plasma was isolated from whole blood collected via submandibular bleed one week post-treatment 
with either LNA29 (n = 14) or saline (n = 12) and was analyzed for levels of total cholesterol (a), 
triglycerides (c), glucose (d), and β -hydroxybutyrate (e). (b) Changes in total plasma cholesterol (∆mg/dL)  
between pre- and post-dosing are shown for each mouse treated with either LNA29 (n = 14) or saline 
(n = 12). *p < 0.05; ***p < 0.005; p-values were calculated by two-tailed unpaired Student’s t-test. Error bars 
represent standard error of the mean.
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Figure 3. RNA-seq identifies lipid synthesis as the most enriched pathway among genes down-regulated 
in mouse liver upon inhibition of miR-29. (a) Deep sequencing of total RNA revealed 612 down-regulated 
genes (blue) and 271 up-regulated genes (purple) in the livers of LNA29-treated mice (n = 6) compared 
to saline-treated (n = 6) controls. (b,c) Results of miRNA target site enrichment analysis shown for down-
regulated (b) and up-regulated genes (c). (d,e) Results of gene ontology (GO) term enrichment analysis 
using NIH David shown for down-regulated (d) and up-regulated genes (e). Vertical dashed lines represent 
corrected p < 0.05. RNA-seq p-values were calculated by one-tailed unpaired Student’s t-test. Percentages 
represent the number of genes from the gene set involved in the pathway divided by the total number of 
genes in the gene set.
www.nature.com/scientificreports/
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Figure 4. Inhibition of miR-29 represses the fatty acid synthesis pathway and reduces fatty acid content 
in the liver. (a) Expression fold-change (FC) by RNA-seq in LNA29-treated mice (n = 6) relative to saline-
treated controls (n = 6) is shown for key genes in the hepatic fatty acid synthesis pathway. p-values were 
calculated by one-tailed unpaired Student’s t-test. (b) RT-qPCR validation of RNA-seq results shown 
for Srebf1, Mlxipl/ChREBP, Acly, Acaca, Fasn and Scd1. Relative abundance (2^-dCt) was compared 
between LNA29-treated (n = 14) and saline-treated (n = 12) mice. Rsp9 was used as the normalizer. (c) 
Densitometry analysis shown for Scd1 protein in livers from LNA29-treated mice (n = 10) compared to 
saline-treated controls (n = 8). β -actin was used as the loading control. Immunoblot results also shown for 
two representative mice from each treatment group. (d) Quantification of radiolabeled acetate incorporation 
into fatty acids in vitro (Huh7 cells) after transfection with LNA29a (10 nM, n = 6) or transfection reagent 
alone (Mock, n = 6). (e) Measurement of total fatty acid levels in the livers of LNA29-treated animals (n = 14) 
compared to saline-treated controls (n = 12). (f) Levels of individual long-chain fatty acids in LNA29-treated 
relative to saline-treated mice. C14:0 (Myristic acid), C16:0 (Palmitic acid), C18:0 (Stearic acid), C18:1 (Oleic 
acid), C18:2 (Linoleic acid), C18:3 (Linolenic acid), C20:1 (Gondoic acid), C20:2 (Eicosadienoic acid), C20:3 
(Homogamalinolenic acid), C20:4 (Arachidonic acid), C20:5 (Eicosapentaenoic acid), C24:0 (Lignoceric acid), 
C22:5 (Docosapentaenoic acid), C22:6 (Docosahexaenoic acid). *p < 0.05; **p < 0.01; ***p < 0.005; p-values 
were calculated by two-tailed unpaired Student’s t-test. Error bars represent standard error of the mean.
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LNA29 alleviates miR-29-mediated repression of anti-lipogenic factors Ahr, Foxo3 and 
Sirt1. To explain the widespread down-regulation of genes in the hepatic fatty acid and cholesterol 
synthesis pathways mediated by LNA29-treatment, we hypothesized that inhibition of miR-29 promotes 
specific anti-lipogenic factors via loss of direct miR-29 targeting. Aryl hydrocarbon receptor (Ahr) 
has been implicated in the suppression of both fatty acid and cholesterol synthesis in the liver30,31. We 
found that Ahr was ~1.5-fold up-regulated in the mouse liver at both the mRNA and protein level by 
LNA29-treatment (Supplementary Table S1, Fig.  6a). Ahr is also widely appreciated as an activator of 
xenobiotic-metabolizing enzymes such as the cytochrome P450s32. RNA-seq data analysis revealed that 
several cytochrome P450 genes were indeed significantly up-regulated (ranging from ~2 to ~7-fold) in 
Figure 5. Inhibition of miR-29 represses the cholesterol synthesis pathway but slightly increases total 
hepatic cholesterol levels. (a) Expression fold-change (FC) by RNA-seq in LNA29-treated mice (n = 6) 
relative to saline-treated controls (n = 6) is shown for key genes in the hepatic cholesterol synthesis 
pathway. p-values were calculated by one-tailed unpaired Student’s t-test. (b,c) RT-qPCR results shown for 
Srebf2, Mvk, Cyp51, Sqle and Idi1 (b) as well as for miR-33a (c), which is co-transcribed with Srebf2. (d) 
Quantification of radiolabeled acetate incorporation into cholesterol in vitro (Huh7 cells) after transfection 
with LNA29a (10 nM, n = 6) or transfection reagent alone (Mock, n = 6). (e) Measurement of total 
cholesterol levels in the livers of LNA29-treated mice (n = 14) compared to saline-treated controls (n = 12). 
*p < 0.05; **p < 0.01; ***p < 0.005; p-values were calculated by two-tailed unpaired Student’s t-test. Error 
bars represent standard error of the mean.
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the livers of LNA29-treated mice, including Cyp1a1, Cyp2b10, Cyp2c40, Cyp2d9, Cyp3a11 and Cyp4a12a 
(Fig. 6b), consistent with elevated Ahr transcriptional activity.
miR-29 is predicted to target the Ahr 3′ UTR at a site that is highly conserved between human and 
mouse (Fig.  6c). To determine if the site is functional, we performed standard 3′ UTR reporter gene 
assays (Methods). In the presence of the miR-29a mimic, relative levels of luciferase activity were reduced 
by more than 50% (Fig.  6d). Furthermore, a highly conservative single point mutation in the miR-29 
target site slightly but significantly rescued this effect (Supplementary Fig. S5). These data support the 
model that inhibition of miR-29 in vivo leads to the loss of miR-29-mediated repression of Ahr and 
thereby promotes the anti-lipogenic activity of Ahr.
In addition to Ahr, the transcription factor forkhead box O3 (Foxo3) and the sirtuin family of 
NAD-dependent deacetylases have also been linked to the suppression of hepatic lipid synthesis33,34. 
Hepatic mRNA levels of a single sirtuin family member, sirtuin 1 (Sirt1), were increased in the 
LNA29-treated mice. Both Sirt1 and Foxo3 were previously validated as direct targets of miR-29 in other 
cell types35,36; therefore, we sought to evaluate whether Sirt1 and Foxo3 protein levels were altered in the 
livers of LNA29-treated mice. Immunoblot analysis revealed that the protein levels of both were increased 
(~1.6-fold) in the livers of LNA29-treated mice (Supplementary Fig. S6). Notably, Ahr and Sirt1 have 
been identified recently as transcriptional activators of Fgf2137–39, an emerging metabolic regulator with 
potential therapeutic value for dyslipidemia, obesity, type 2 diabetes and related diseases40,41. We demon-
strated that Fgf21 mRNA levels were increased in the livers of LNA29-treated mice (Supplementary Table 
S1). These data lend further support to the model that inhibition of miR-29 leads to the suppression of 
lipogenic programs likely in part through elevated expression and activity of the anti-lipogenic factors 
Ahr and Sirt1 (Fig. 7).
Figure 6. Inhibition of miR-29 alleviates miR-29-mediated repression of the anti-lipogenic transcription 
factor Ahr. (a) Densitometry analysis for hepatic Ahr protein from LNA29-treated mice (n = 5) compared 
to saline-treated controls (n = 3). β -actin was used as the loading control. Immunoblot results also shown 
for two representative mice from each treatment group. (b) Expression fold-change (FC) by RNA-seq in 
LNA29-treated mice (n = 6) relative to saline-treated controls (n = 6) is shown for genes known to be 
transcriptionally activated by Ahr. p-values were calculated by one-tailed unpaired Student’s t-test. (c) A 
diagram of the predicted base pairing between miR-29 and the Ahr 3′ UTR sequence of both mouse and 
human is shown. (d) Effects of miR-29a mimic (10 nM) in HEK293T cells on the activity of Firefly (FL) 
luciferase with or without the Ahr 3′ UTR normalized to Renilla luciferase (RL) are shown. ***p < 0.005; 
*p < 0.05; p-values were calculated by two-tailed unpaired Student’s t-test. Error bars represent standard 
error of the mean.
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Discussion
In this study, we used LNA technology to investigate the effects of loss of miR-29 function in vivo on 
lipid levels. We demonstrated that the knockdown of miR-29 in mice led to a significant reduction in 
plasma cholesterol and triglyceride levels, as well as reduced fatty acid content in the liver. RNA sequenc-
ing analysis revealed aberrant expression levels for over 850 genes, including 612 down-regulated genes 
that were most significantly over-represented in lipid synthesis pathways. Real-time quantitative PCR 
and immunoblot analyses confirmed altered cholesterologenic and lipogenic transcriptional profiles in 
the livers of mice treated with LNA29. We also demonstrated that loss of miR-29 function increased the 
mRNA and protein levels of the transcription factors Ahr and Foxo3, as well as the deacetylase Sirt1.
Our findings suggest that the loss of miR-29 leads to altered Ahr transcriptional activity. Previous 
studies have shown that miR-29 directly targets Sirt1 and Foxo335,36 and our study reveals that miR-29 
likely also directly targets and represses Ahr. The activation of each of Ahr, Sirt1, and Foxo3 has been 
linked to the suppression of lipid synthesis31–34 (Fig. 7). Future work should investigate whether one or 
more of these factors are required/essential for miR-29-mediated control of lipid levels. It must be noted 
that activation of Sirt1 can also stimulate histone deacetylase 1 (HDAC1), a protein that in some contexts 
may promote cholesterol synthesis42. However, Sirt1 control of HDAC1 has been demonstrated primarily 
in cell types other than those within liver, most notably neurons43,44. In the fasted liver, Sirt1 control of 
HDAC1 has not been well investigated. Contrastingly, Sirt1-mediated repression of hepatic cholesterol 
and fatty acid synthesis has been reported in numerous studies33,45,46. The relevance of HDAC1 to the role 
of Sirt1 in miR-29-mediated regulation of lipid synthesis merits further detailed investigation.
Our study focused on direct (Ahr, Foxo3) and indirect (Sirt1) regulators of transcription as mediators 
of the effect of miR-29 on lipogenic programs in the liver. However, other mechanisms are also possible. 
One notable possibility involves insulin induced gene 1 and 2 (Insig1 and Insig2), which sequester Srebp1 
and Srebp2 in the endoplasmic reticulum under high sterol conditions, thereby suppressing fatty acid 
and cholesterol synthesis. LNA29 treated mouse livers exhibited a significant increase in Insig2 mRNA 
levels (Supplementary Table S1). It is possible that up-regulation of Insig2 contributes to decreased cho-
lesterol synthesis in LNA29 treated mice.
We showed through in vitro acetate incorporation assays that inhibition of miR-29 dramatically 
reduced de novo synthesis of both fatty acids and cholesterol. In the miR-29 knockdown mice hepatic 
fatty acid levels were reduced, whereas cholesterol levels were slightly elevated. These findings raise 
the possibility that miR-29 regulates not only cholesterol synthesis, but also other important pathways 
that contribute to overall cholesterol homeostasis. Further detailed investigation is required to establish 
how miR-29 coordinates control of cholesterol synthesis, uptake, storage, metabolism, and/or efflux to 
fine-tune intracellular cholesterol levels, such as in the case of miR-223, which we recently demonstrated 
controls not only hepatic cholesterol synthesis, but high-density lipoprotein cholesterol uptake and cel-
lular cholesterol efflux as well25.
Our findings indicate that miR-29 is a critical regulator of cholesterol and fatty acid synthesis. A 
recent study reported that inhibition of miR-29a leads to accumulation of fat in the liver47. However, a 
notable distinction between that study and ours is that we inhibited all three miR-29 family members as 
opposed to only miR-29a (Fig. 1). We also performed transcriptome-wide analysis of liver gene expres-
sion profiles to firmly establish the efficacy of miR-29abc inhibition (Fig.  3), in contrast to evaluating 
only a few known target genes47. These and other methodological differences between the studies merit 
further detailed investigation in order to improve our understanding of miR-29 functions in the liver and 
the dose-dependent nature of those functions.
miR-29 has been linked to several other biological processes, including cell proliferation48, interferon 
response49, extracellular matrix homeostasis50, and gluconeogenesis51. Decreased expression of miR-29 
has been associated with multiple disease pathologies, including organ fibrosis and rhabdomyosarcoma52. 
It must be noted that it is not known whether the regulatory effects of miR-29 in vivo are greater on some 
pathways compared to others. To determine whether miR-29 represents a candidate therapeutic target 
Figure 7. Schematic of the putative molecular mechanism underlying the effects of LNA29 treatment. 
In this model, under normal conditions, miR-29 may promote lipogenesis through suppression of Ahr, Sirt1 
and Foxo3. Upon LNA29 treatment, miR-29 activity is suppressed, and Ahr, Sirt1, and Foxo3 levels are 
elevated, leading to reduced cholesterol and fatty acid synthesis.
www.nature.com/scientificreports/
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for lipid metabolic disorders, future work must carefully assess the effects of long-term inhibition of 
miR-29 on not only hepatic and circulating lipid profiles, but also additional phenotypes such as hepatic 
proliferative capacity, inflammation, fibrosis, and insulin sensitivity.
Methods
Animal Studies. Eight week old C57BL/6 J female mice were purchased from Jackson Laboratories 
(Bar Harbor, ME) and maintained on a 12 hr light/dark cycle with access to a standard chow diet and 
H2O ad libitum. After a minimum of a 10 day period of acclimation, the animals were weighed and 
injected via tail vein with either RNase-free sterile saline (BioO Scientific; Austin, TX) or LNAs against 
mmu-miR-29a-3p (5′ ATTTCAGATGGTGCT 3′ ) and mmu-miR-29bc-3p (5′ ATTTCAAATGGTGCT 
3′ ) or mmu-miR-27b-3p (5′ ACTTAGCCACTGTGA 3′ ) at 20mg/kg each (Exiqon; Woburn, MA). Blood 
was collected via submandibular bleed within one week before dosing with LNA and again six days 
post-dosing. Seven days after dosing with LNA, following an 18 hour fast, the animals were sacrificed 
by cervical dislocation without anesthesia and organs were collected. Organs were flash frozen in liquid 
nitrogen and kept at −80oC for further analysis. All animal work was performed in accordance with 
the Public Health Service Policy on Humane Care and Use of Laboratory Animals, and all studies were 
approved by the Institutional Animal Care and Use Committee (IACUC) at the University of North 
Carolina at Chapel Hill.
RT-qPCR. Total RNA was isolated from tissues using the Total RNA Purification kit (Norgen; Ontario, 
Canada). One ug of total RNA was used for reverse transcription with the High Capacity RNA to cDNA 
kit (Life Technologies; Grand Island, NY) and 200 ng RNA was used for reverse transcription with the 
TaqMan microRNA Reverse Transcription kit (Life Technologies). Both miRNA and gene expression 
qPCR were performed using TaqMan assays with either TaqMan Universal PCR Master Mix (miRNA 
qPCR) or TaqMan Gene Expression Master Mix (Life Technologies) per the manufacturer’s protocol, 
on a BioRad CFX96 Touch Real Time PCR Detection System (Bio-Rad Laboratories, Inc.; Richmond, 
CA). Reactions were performed in triplicate using either U6 (miRNA) or Rps9 (gene expression) as the 
normalizer.
Plasma metabolite analysis. Plasma was isolated by spinning whole blood for 10 min at 10000 g, 
4 °C. Plasma was used to measure total cholesterol, glucose, triglycerides, β -hydroxybutyrate and ala-
nine aminotransferase (ALT) at the UNC Nutrition Obesity Research Center (NORC) Nutritional 
Biochemistry & Molecular Biology core facility.
RNA deep sequencing. RNA was isolated as described previously from hepatic tissue from 
mice treated with LNA29 or saline. Libraries for RNA-seq were prepared using the Illumina TruSeq 
polyA + Sample Prep Kit. Single read sequencing (x100) was carried out on the Illumina HiSeq 2000 
platform. Mapping of sequencing reads was performed by MapSplice253 and quantification of gene 
expression by RSEM54. Differentially expressed genes in livers of LNA29-treated mice compared to 
saline-treated controls were identified by one-tailed, unpaired Student’s t-test. Genes were considered 
significantly up- or down-regulated if they had a fold change ≥+ /−1.5 at a p-value ≤ 0.05. Gene ontol-
ogy analysis was performed using both NIH DAVID and QIAGEN’s Ingenuity® Pathway Analysis (IPA®, 
QIAGEN Redwood City; www.qiagen.com/ingenuity).
Bioinformatics. 3′ UTRs of significantly up- and down-regulated genes were analyzed for enrichment 
of predicted miRNA target sites as previously described55.
Western blotting. Protein was isolated using RIPA buffer (Sigma-Aldrich; St. Louis, MO) and quan-
titated using the Pierce® Microplate BCA Protein Assay Kit – Reducing Agent compatible (Thermo 
Scientific Pierce; Rockford, IL). An Any kDTM Mini-Protean TGXTM precast gel (Bio-Rad Laboratories, 
Inc.; Richmond, CA) was run for 2 hours at 120 v, and protein was transferred to a nitrocellulose 
membrane using the Bio-Rad Midi Transfer Pack on the Bio-Rad Trans-Blot® Turbo Blotting System. 
Membranes were blocked in 5% non-fat dry milk in TBST for 1 hour at room temperature (RT) while 
shaking. Primary antibody incubation was done in 4% milk/TBST for 16 hours at 4 °C with shaking as fol-
lows: Ahr—2.5 ug/ml (Abcam; Cambridge, MA), Foxo3, Scd1 and Sirt1—1 ug/ml (Abcam). Membranes 
were washed 3 times for 10 minutes with TBST at RT with shaking and then probed with secondary Ab 
in 1% milk (Goat anti-rabbit from Abcam: Ahr, Foxo3, Scd1; or anti-mouse – Cell Signaling; Danvers, 
MA: Sirt1) for 1 hour at RT with shaking. Finally, membranes were washed 3 times in TBST for 10 min-
utes at RT with shaking and signal was detected using the Amersham™ ECL™ Prime Western Blotting 
Detection Reagent (GE Healthcare Life Sciences; Piscataway, NJ). Membranes were exposed to film and 
images were analyzed using the Image Studio Lite software program (Licor, Lincoln, NE). The control 
antibody used was β -actin peroxidase (Sigma-Aldrich), diluted 1:40000 in 1% milk/TBST, probed for 
30 minutes at room temperature while shaking and subject to ECL blotting detection reagent and film 
exposure. Protein concentration was expressed as fold increase relative to the control.
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Luciferase assay. HEK293T cells were maintained in 25 mM glucose DMEM (Sigma-Aldrich) 
supplemented with 10% FBS and 2 mM L-glutamine (Invitrogen; Grand Island, NY), and cultured 
in a humidified incubator at 37 °C and 5% CO2. HEK293T cells were seeded into 24 well plates and 
allowed to grow overnight. Once the cells were approximately 70% confluent, they were trans-
fected with 200 ng of pEZX-MT01 empty vector, vector containing the 3′ UTR of HMGCR or AHR 
(GeneCopoeia, Rockville, MD) and 10 nM miRIDIAN microRNA hsa-miR-29a-3p mimic (Sequence: 5′ 
UAGCACCAUCUGAAAUCGGUUA 3′ , Dharmacon; Lafayette, CO). Transfection was performed using 
Lipofectamine 2000 (Life Technologies). After 48 hours, the cells were lysed and luciferase activity was 
measured using the Luc-Pair luciferase assay kit (Agilent; Santa Clara, CA) on a GloMax® 96 Microplate 
Luminometer (Promega; Madison, WI). Site-directed mutagenesis was performed with the QuikChange 
II XL Site-Directed Mutagenesis Kit (Agilent).
Acetate incorporation assay. Human hepatoma cells (Huh7) were seeded into 6-well plates at a 
density of 1 × 105 cells/mL. After overnight growth, cells were transfected with either LNA29a, LNA29bc, 
or transfection reagent only (mock). Forty-eight hours after transfection, media was removed and 
replaced with DMEM low glucose lipoprotein deficient serum (LPDS) media. Seventeen hours later, low 
glucose media was removed and replaced with fresh serum-free low glucose media (cholesterol free) 
with 1uCi3H-acetic acid per well (0.5uCi/ml media) and incubated for 6 hours. Cells were washed twice 
with 1X Phosphate Buffered Saline. Two mL 3:2 hexane:isopropanol were added to each well; the cells 
were allowed to sit for 2 hours then placed in glass vials. Samples were dried down under nitrogen and 
30 μ l of cold 0.1 μ g cholesterol:cholesteryloleate was added. Thirty μ l of resuspended lipids were placed 
onto a plate and thin layer chromatography was performed (petroleum ether:diethyl ether:acetic acid). 
Spots were resolved with iodine, and cholesteryl ester, cholesterol and triglyceride spots were cut out 
and placed in 10 mL scintillation fluid. Total protein for each well was quantified using the BCA assay.
Liver fatty acid analysis. Total lipids were extracted from 100 mg of liver tissue, first with metha-
nol (MeOH)/chloroform (CHCl3), then with MeOH/CHCl3/H20 (2:1:0.8) at the UNC Nutrition Obesity 
Research Center (NORC) Nutritional Biochemistry and Molecular Biology Core. Lipids were saponified 
and the fatty acids trans-methylated. The lower phase containing the fatty acid methyl esters was care-
fully transferred to a clean tube and evaporated to dryness under nitrogen. Fatty acid methyl esters were 
resuspended in 50 μ l CHCl3:undecane (1:4) and analyzed using an Agilent 7890A GC system equipped 
with a capillary column coated with 70% cyanopropyl polysilphenylene-silozane (10 m × 100 μ m 
ID-BPX70 0.2 um; SGE, Austin, TX). Data was analyzed with the Agilent GC Software ChemStation 
Rev. B03.02-SR2. Heptadecanoic acid (17:0) was added to the samples as an internal standard to correct 
for recovery. Individual fatty acids were identified by comparing their retention times with fatty acid 
standards (Nu Chek Prep, Elysian, MN) and quantified by comparing their peak areas with standards.
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